Pfizer stays the course on 2024 outlook after delivering better earnings than Wall Street forecast
In the fourth quarter, Pfizer said it booked 8% operational revenue growth outside its market-leading COVID vaccine, Comirnaty, and treatment, Paxlovid.
Read More